Michael Goldberg

Dr. Michael Goldberg is the Founder and CEO of Surge Therapeutics.  Prior to this, he was a member of the faculty at Harvard Medical School and Dana-Farber Cancer Institute.  Dr. Goldberg’s research has been published in Cell, Nature, Science, Nature Biotechnology, and Science Translational Medicine.  Dr. Goldberg holds his Hon. B.Sc. in Biological Chemistry from the University of Toronto, his M/Phil. In BioScience Enterprise from the University of Cambridge, and his Ph.D. in Biological Chemistry from the MIT, where is also completed his post-doctoral training.